|
gptkbp:instanceOf
|
gptkb:drug
|
|
gptkbp:administeredBy
|
intravenous infusion
|
|
gptkbp:approvalYear
|
2004
|
|
gptkbp:approvedBy
|
gptkb:FDA
|
|
gptkbp:ATCCode
|
L04AA23
|
|
gptkbp:brand
|
gptkb:natalizumab
|
|
gptkbp:CASNumber
|
189261-10-7
|
|
gptkbp:chemicalFormula
|
C6470H10052N1732O2010S42
|
|
gptkbp:contraindication
|
immunocompromised patients
history of PML
|
|
gptkbp:firstApprovedCountry
|
gptkb:United_States
|
|
gptkbp:halfLife
|
11 days
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Tysabri
|
|
gptkbp:indication
|
relapsing forms of multiple sclerosis
moderate to severe Crohn's disease
|
|
gptkbp:isMonoclonalAntibody
|
true
|
|
gptkbp:KEGGID
|
D04124
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:manufacturer
|
gptkb:Biogen
gptkb:Elan
|
|
gptkbp:mechanismOfAction
|
alpha-4 integrin antagonist
|
|
gptkbp:MedlinePlusID
|
a605007
|
|
gptkbp:monoclonalAntibodyType
|
humanized
|
|
gptkbp:pregnancyCategory
|
C
|
|
gptkbp:PubChem_CID
|
1201582
DB00108
|
|
gptkbp:riskEvaluationMitigationStrategy
|
required
|
|
gptkbp:routeOfAdministration
|
intravenous
|
|
gptkbp:RxNorm
|
32968
|
|
gptkbp:sideEffect
|
gptkb:progressive_multifocal_leukoencephalopathy
fatigue
headache
allergic reaction
|
|
gptkbp:target
|
gptkb:alpha-4_beta-1_integrin
gptkb:alpha-4_beta-7_integrin
|
|
gptkbp:UNII
|
J2R2WSB9L9
|
|
gptkbp:usedFor
|
gptkb:Crohn's_disease
multiple sclerosis
|
|
gptkbp:bfsParent
|
gptkb:Biogen
|
|
gptkbp:bfsLayer
|
5
|